PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.07
0.06 - 0.24
4.46M / 3.59M (Avg.)
-1.65 | -0.04
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
153.85%
Net income growth above 1.5x CRN.AX's 47.33%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
15.17%
Some D&A expansion while CRN.AX is negative at -26.77%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
100.00%
SBC growth well above CRN.AX's 114.22%. Michael Burry would flag major dilution risk vs. competitor’s approach.
100.00%
Slight usage while CRN.AX is negative at -29.04%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
100.00%
AR growth well above CRN.AX's 165.67%. Michael Burry would fear inflated sales or less stringent credit controls vs. competitor.
-100.00%
Both reduce yoy inventory, with CRN.AX at -104.07%. Martin Whitman would find a widespread caution or cyclical demand drop in the niche.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth well above CRN.AX's 47.16%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-258.19%
Negative yoy while CRN.AX is 384.41%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
169.21%
Operating cash flow growth below 50% of CRN.AX's 16496.02%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
50.56%
CapEx growth well above CRN.AX's 58.16%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Purchases growth of 100.00% while CRN.AX is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
No Data
No Data available this quarter, please select a different quarter.
-40.47%
Both yoy lines negative, with CRN.AX at -37.14%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-30.36%
We reduce yoy invests while CRN.AX stands at 67.40%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
241.90%
We repay more while CRN.AX is negative at -7971.06%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.